New stock news: The prospectus for the Hong Kong IPO of Cansino Biologics (688136.SH) has expired.

According to the Securities Times app, the Hong Kong stock prospectus submitted by Ke Xing Biopharmaceutical Co., Ltd. (referred to as "Ke Xing Pharmaceutical" 688136.SH) on November 6, 2025, will expire after 6 months on May 6, 2026. At the time of submission, CICC International was the exclusive sponsor.